Defendant / Appellee:	Forest Laboratories, Inc., Panadol, Nurofen, Maury M. Tepper, III, (Official & Individual Capacity), Gabapentin, Endo Pharmaceuticals, Inc., Tramal, Johnson & Johnson, Inc., Pfizer Consumer Products, Charles Pfizer Estate, Novartis International AG, Charles F. Erhart Estate, Jim Cannon, Teikoku Pharma USA, Inc., Voltaren Canada, INN, Ibruprofen, Ciba Geigy Limited, Voltaren Australia, Neurontin, Johnson & Johnson Estate, Gralise, Qualitest and Vintage Pharmaceuticals, Lidoderm Corporation, (Foreign & Domestic), Dr. Stewart Adams Estate, (Foreign and Domestic), Tramal Corporation, Ciba Geigy Corporation, Tramadol, Reckitt Benckiser Estate, (Foreign & Domestic), Sensodyne Corporation, Pfizer, Inc., Forest Pharmaceuticals, Pharmacia LLC, Cataflam, Diclofenac, GSK, Arex, Bristol-Myers Squibb Company, JP John, Voltaren, Salonpas, Teikoku Seiyaku Corporation, Ltd., Lidoderm Patch, Naproxen Steroid, Pregabalin, Boots, Nuprin, Allergan PLC, Solarcaine, Anaprox, Maxiclear, Citalopraim, Advil, Zytram, Greenstone, Solutia, Naprelan, Novartis Corporation, Ultram, Sinsinpas, Versatis Corporation, Whitehall Laboratories, Division of American Home Products, O'Neil Jones & Feldman Estate, BAN, Aleve, Denice Torres, Monsanto Company, USAN, Celexa, GlaxoSmithKline LLC, Sensodyne Toothpaste Corporation, Naprosyn, Motrin, Scilex, AAN and Lexapro
Plaintiff / Appellant:	Robert W. Johnson
Case Number:	20-617
Filed:	February 18, 2020
Court:	U.S. Court of Appeals, Second Circuit
Nature of Suit:	CIVIL RIGHTS-Other

Access additional case information on PACER

Access the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.